THOR 76 Crude
Version 1.c2b55dfc · 2026-09-13
| CAS No. | Not available |
| Chemical Name | THOR 76 Crude |
| Synonyms | THOR-76-Crude， THOR76Crude |
| SMILES | CCCCCCCC/C=C\CCCCCCCC(=O)N(CCCNCCCCNCCCN(C(=O)CCCCCCC/C=C\CCCCCCCC)C(CCCCCCC/C=C\CCCCCCCC)C(=O)NCCCN1CCOCC1)C(CCCCCCC/C=C\CCCCCCCC)C(=O)NCCCN1CCOCC1 |
| Formula | C98H186O6N8 |
| M.Wt | 1,572.62 |
| Purity | 98% |
| Storage | Original product: up to 1 year under the storage conditions stated on the vial, kept tightly sealed. Stock solutions: aliquots at -20°C, generally up to one month. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Not available |
THOR 76 is an ionizable lipid developed for lung-targeted mRNA delivery, synthesized via a high-throughput Ugi four-component reaction (U4CR). It combines spermine (N3, amine core), oleyl aldehyde (A2), oleic acid (C2), and a morpholine-functionalized isonitrile (D3). Remarkably, its crude reaction mixture outperforms purified forms in efficacy, suggesting synergistic impurities or intermediates enhance function. Formulated into lipid nanoparticles (LNPs) with cholesterol, DOPE, and PEG-lipid, THOR 76 LNPs exhibit exceptional lung tropism with secondary spleen affinity after intravenous administration. They efficiently transfect pulmonary endothelial cells, enabling robust gene expression (e.g., Cre recombinase) and significant CRISPR-Cas9-mediated gene editing (1.22% at 0.1 mg/kg dose) in the lungs. With a particle size <150 nm, positive zeta potential, and >90% mRNA encapsulation, THOR 76 achieves targeted delivery while minimizing off-target effects in the liver. Its design overcomes limitations of cationic helper lipids, offering a potent, tolerable platform for treating pulmonary genetic disorders and cancers.
Specifications shown are product-page values, not batch test results.
Read Instructions for Use →